Diablo Clinical Research

Portland, United States· Est. 1995

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Diablo Clinical Research is a long-established, private clinical research services provider that has recently been integrated into the Flourish Research Network, now operating as Flourish Research – Walnut Creek. With over 1,000 studies completed and a database of more than 18,000 patients, the company leverages deep investigator and staff experience to conduct trials in areas like diabetes, vaccines, weight loss, and medical devices. Its business model is entirely service-based, generating revenue from sponsors and CROs for conducting clinical trials, positioning it as a specialized site within the broader clinical research ecosystem.

Celiac DiseaseDiabetesDiabetic NeuropathyMigraineObesity/Weight LossVaccinesHeart DiseaseHigh Blood PressureHigh CholesterolMedical DevicesArthritisBack PainFibromyalgiaOsteoporosis/OsteopeniaWomen's HealthMen's Health

Technology Platform

Operational clinical trial execution platform comprising an experienced investigator team (MDs with 25+ years avg. experience), a dedicated facility with outpatient/inpatient units, and a proprietary patient database of 18,000+ individuals for recruitment.

Opportunities

Leveraging integration into the Flourish Research Network to access a larger pipeline of sponsor studies and operational resources.

High demand in core therapeutic areas like diabetes, obesity, and vaccines presents sustained growth opportunities.

Increasing sponsor focus on diverse patient recruitment aligns with the company's community inclusion ethos.

Risk Factors

Revenue dependency on a variable sponsor study pipeline creates volatility.

Intense competition from other research sites and networks threatens market share.

Patient recruitment delays and regulatory compliance issues pose operational and financial risks.

Competitive Landscape

Operates in the highly fragmented clinical trial site sector, competing against other independent sites, hospital-based research centers, and large site networks like ICON plc (PRA Health Sciences) and Syneos Health on a site-level basis. Differentiation is based on therapeutic expertise, patient recruitment speed, data quality, and investigator experience.